VERU Inc., transitioning from a single-product company to a clinical-stage biopharmaceutical firm, reported ongoing advancement of its dual late-stage pipeline targeting cardiometabolic and inflammatory diseases. The company recently completed enrollment in its Phase 2b study of enobosarm, a selective androgen receptor modulator designed to improve weight loss outcomes by preserving lean muscle during GLP-1 receptor agonist treatment. Meanwhile, sabizabulin development aims to address inflammation in atherosclerotic cardiovascular disease. Despite clinical progress, VERU faces financing headwinds due to SEC rules limiting capital raises and a sub-$75 million public float. Current cash supports near-term operations, but the firm will require additional funding to sustain development beyond the upcoming milestones.